Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 313,132
  • Shares Outstanding, K 265,366
  • Annual Sales, $ 160,180 K
  • Annual Income, $ -69,410 K
  • EBIT $ 18 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.38
  • Price/Sales 1.32
  • Price/Cash Flow N/A
  • Price/Book 7.52

Options Overview Details

View History
  • Implied Volatility 253.76% (-188.75%)
  • Historical Volatility 71.35%
  • IV Percentile 94%
  • IV Rank 50.90%
  • IV High 442.51% on 02/19/26
  • IV Low 58.06% on 05/14/25
  • Expected Move (DTE 26) 0.2890 (24.49%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 89
  • Volume Avg (30-Day) 419
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 31,877
  • Open Int (30-Day) 28,912
  • Expected Range 0.8910 to 1.4690

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate 0.03
  • Low Estimate -0.06
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +3.51%
on 02/20/26
1.6000 -26.25%
on 02/12/26
-0.1600 (-11.94%)
since 01/20/26
3-Month
1.1400 +3.51%
on 02/20/26
1.7300 -31.79%
on 12/22/25
-0.3600 (-23.38%)
since 11/20/25
52-Week
1.1400 +3.51%
on 02/20/26
4.0787 -71.07%
on 07/11/25
-0.7300 (-38.22%)
since 02/20/25

Most Recent Stories

More News
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...

AKBA : 1.1800 (unch)
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.1800 (unch)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.1800 (unch)
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

 Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental...

AKBA : 1.1800 (unch)
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.1800 (unch)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.1800 (unch)
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.

QTTB : 4.69 (+9.84%)
AKBA : 1.1800 (unch)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.1800 (unch)
Q32 Bio Sells Complement Inhibitor ADX-097

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --

AKBA : 1.1800 (unch)
QTTB : 4.69 (+9.84%)
Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease...

AKBA : 1.1800 (unch)
QTTB : 4.69 (+9.84%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.2500
2nd Resistance Point 1.2200
1st Resistance Point 1.2000
Last Price 1.1800
1st Support Level 1.1500
2nd Support Level 1.1200
3rd Support Level 1.1000

See More

52-Week High 4.0787
Fibonacci 61.8% 2.9561
Fibonacci 50% 2.6093
Fibonacci 38.2% 2.2626
Last Price 1.1800
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar